Skip to main content

Table 3 Mixed-effects linear regressions predicting the change in CoV of stride time (n = 240 measures and n = 120 participants)

From: Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study

 

Change in CoV of stride time*

Model 1†

Model 2†

β

95% CI

P-value

β

95% CI

P-value

Drugs effect

      

     Use of CEIs

−0.067

[−0.381; 0.246]

0.674

−0.193

[−0.512; 0.125]

0.234

     Use of memantine

0.179

[−0.138; 0.496]

0.268

−0.014

[−0.341; 0.313]

0.933

Time effect‡

0.019

[−0.232; 0.269]

0.885

0.019

[−0.222; 0.259]

0.878

Drugs x time interaction

      

     No treatment

Ref

Ref

     Use of CEIs

0.186

[−0.153; 0.526]

0.282

0.190

[−0.138; 0.518]

0.256

     Use of memantine

−0.385

[−0.728; -0.415]

0.028

−0.371

[−0.702; -0.041]

0.028

Age

   

0.000

[−0.000; 0.000]

0.811

Female gender

   

−0.229

[−0.453; -0.004]

0.046

BMI

   

−0.0004

[−0.0000; 0.0008]

0.053

Number of drugs daily taken¶

   

0.011

[−0.019; 0.041]

0.490

Use of psychoactive drugs#¶

   

0.081

[−0.278; 0.116]

0.422

MMSE score¶

   

−0.028

[−0.046; -0.009]

0.003

Walking speed¶

   

−0.003

[−0.006; 0.0001]

0.147

  1. CI = confidence interval; CEIs: acetylcholinesterase inhibitors; BMI: body mass index; MMSE: Folstein's Mini-Mental State Examination; CoV: coefficient of variation; β: coefficient of regression beta corresponding to change in CoV of stride time; *: normalized by taking the square-root and coded as a continuous variable; †: separated models (Model 1: non-adjusted on baseline characteristics; Model 2: full adjusted model); ‡: time between before and after introduction of anti-dementia drugs; #: benzodiazepines, antidepressants or neuroleptics at baseline assessment; ¶: at baseline assessment (i.e., before treatment); P-value significant (i.e., P < 0.05) indicated in bold.